Bio-Path Holdings (Bio-Path Holdings) Cash Flow from Financing : $0.17 Mil (TTM As of Mar. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Bio-Path Holdings Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2024, Bio-Path Holdings received $0.17 Mil more from issuing new shares than it paid to buy back shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Bio-Path Holdings earned $0.17 Mil on financial activities for the three months ended in Mar. 2024.

Bio-Path Holdings Cash Flow from Financing Historical Data

The historical data trend for Bio-Path Holdings's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Path Holdings Cash Flow from Financing Chart

Bio-Path Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Financing

Get a 7-Day Free Trial

27.78

4.29

20.01

1.73

2.20

Bio-Path Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash Flow from Financing	Get a 7-Day Free Trial															-	-	-	-	0.17

Bio-Path Holdings Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Bio-Path Holdings's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

	Cash Flow from Financing		(A: Dec. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	1.677	+	0	+	0	+	0	+	0	+	0.526
=	2.20

Bio-Path Holdings's Cash from Financing for the quarter that ended in Mar. 2024 is:

	Cash Flow from Financing		(Q: Mar. 2024 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0.174	+	0	+	0	+	0	+	0	+	0
=	0.17

Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.17 Mil.

Bio-Path Holdings (NAS:BPTH) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Bio-Path Holdings's issuance of stock for the three months ended in Mar. 2024 was $0.17 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Bio-Path Holdings's repurchase of stock for the three months ended in Mar. 2024 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Bio-Path Holdings's net issuance of debt for the three months ended in Mar. 2024 was $0.00 Mil. Bio-Path Holdings received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Bio-Path Holdings's net issuance of preferred for the three months ended in Mar. 2024 was $0.00 Mil. Bio-Path Holdings paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Bio-Path Holdings's cash flow for dividends for the three months ended in Mar. 2024 was $0.00 Mil. Bio-Path Holdings received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Bio-Path Holdings's other financing for the three months ended in Mar. 2024 was $0.00 Mil. Bio-Path Holdings received $0.00 Mil on other financial activities.

Bio-Path Holdings Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Bio-Path Holdings's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Path Holdings (Bio-Path Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Path Holdings Inc (NAS:BPTH) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

IBPB:Germany

Address

4710 Bellaire Boulevard, Suite 210, Bellaire, TX, USA, 77401

Website

https://www.biopathholdings.com

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003.

Executives

Aline Sherwood	director	347 BRANDYWINE DRIVE, IRWIN PA 15642
Tamaro Martina Molsbergen	director	1307 SUMMERHILL DRIVE, MALVERN PA 19355
Mark P Colonnese	director	4674 ANDREA POINTE, MARIETTA GA 30062
Peter Henry Nielsen	director, officer: President, CEO & CFO	20651 PRINCE CREEK, KATY TX 77450
Paul Aubert	director	4710 BELLAIRE BOULEVARD, SUITE 210, BELLAIRE TX 77401
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Heath Cleaver	director	4010 BALSAM FIR LN., SPRING TX 77386
Ulrich W. Mueller	officer: COO & Secretary	17841 6TH AVE NW, SHORELINE WA 98177
Amy Sing	director	C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
Michael J. Garrison	director	2626 SOUTH LOOP, SUITE 180, HOUSTON TX 77054
Douglas P Morris	director	550 MADISON AVENUE, SUITE 3206, NEW YORK NY 10022
Gillian C Ivers-read	director	C/O PHARMION CORPORATION, 2525 28TH STREET, BOULDER CO 80301
Thomas E Garrison	director	P O BOX 150248, OGDEN UT 84415